Liu Lining, Liu Yifan, Yuan Min, Xu Liming, Sun Huanxia
Department of Rheumatology, Liaocheng People 's Hospital, Shandong, China.
Department of Rheumatology, Liaocheng People 's Hospital, Shandong, China.
Biochem Biophys Res Commun. 2017 Oct 21;492(3):453-460. doi: 10.1016/j.bbrc.2017.08.075. Epub 2017 Aug 26.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, and its pathogenesis remains mostly unknown. MicroRNAs (miRs) has drawn much attention as a crucial regulator of autoimmune diseases. In this study, we demonstrated that miR-873 expression was significantly up-regulated in patients with SLE, and its expression was positively associated with the disease severity. CD4 T cells, especially the Th17 subset, were found to be the major source of miR-873 expression. Using gain- and loss-of-function approaches, we further showed that miR-873 could facilitate the differentiation of CD4 T cells into Th17 lineage. Moreover, forkhead box O1 (Foxo1), one member of the Foxo family, was identified as a novel target gene of miR-873, and Foxo1 has been known as an inhibitor of Th17 cell differentiation. Foxo1 was observed to be markedly decreased in PBMC of patients with SLE. Notably, in vivo lentivirus-mediated inhibition of miR-873 significantly alleviated the disease severity of spontaneous SLE in MRL/lpr mice, with down-regulated levels of autoantibodies, proteinuria, and IL-17A. Our data reveal a novel mechanism in which the elevated miR-873 in PBMC of SLE promotes Th17 cell differentiation through down-regulation of Foxo1. In vivo blockade of miR-873 may serve as a novel therapeutic approach in the treatment of SLE.
系统性红斑狼疮(SLE)是一种慢性自身免疫性疾病,其发病机制大多仍不清楚。微小RNA(miR)作为自身免疫性疾病的关键调节因子已备受关注。在本研究中,我们证明miR-873在SLE患者中表达显著上调,且其表达与疾病严重程度呈正相关。发现CD4 T细胞,尤其是Th17亚群,是miR-873表达的主要来源。通过功能获得和功能丧失方法,我们进一步表明miR-873可促进CD4 T细胞向Th17谱系分化。此外,叉头框O1(Foxo1),Foxo家族的一员,被鉴定为miR-873的一个新靶基因,并且Foxo1已知是Th17细胞分化的抑制剂。观察到SLE患者外周血单个核细胞(PBMC)中的Foxo1明显减少。值得注意的是,体内慢病毒介导的miR-873抑制显著减轻了MRL/lpr小鼠自发性SLE的疾病严重程度,自身抗体、蛋白尿和IL-17A水平下调。我们的数据揭示了一种新机制,即SLE患者PBMC中升高的miR-873通过下调Foxo1促进Th17细胞分化。体内阻断miR-873可能作为治疗SLE的一种新的治疗方法。